154 related articles for article (PubMed ID: 32231510)
1. Cytomegalovirus Enterocolitis in a Patient with Refractory Immune-Related Colitis.
Furuta Y; Miyamoto H; Naoe H; Shimoda M; Hinokuma Y; Miyamura T; Miyashita A; Fukushima S; Tanaka M; Sasaki Y
Case Rep Gastroenterol; 2020; 14(1):103-109. PubMed ID: 32231510
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis.
Franklin C; Rooms I; Fiedler M; Reis H; Milsch L; Herz S; Livingstone E; Zimmer L; Schmid KW; Dittmer U; Schadendorf D; Schilling B
Eur J Cancer; 2017 Nov; 86():248-256. PubMed ID: 29055840
[TBL] [Abstract][Full Text] [Related]
3. Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis.
Lankes K; Hundorfean G; Harrer T; Pommer AJ; Agaimy A; Angelovska I; Tajmir-Riahi A; Göhl J; Schuler G; Neurath MF; Hohenberger W; Heinzerling L
Oncoimmunology; 2016 Jun; 5(6):e1128611. PubMed ID: 27471608
[TBL] [Abstract][Full Text] [Related]
4. A case of perforated immune-related colitis complicated by cytomegalovirus infection during treatment of immune-related adverse effect in lung cancer immunotherapy.
Nakai M; Kai Y; Suzuki K; Matsuda M; Kikukawa S; Masuda H; Soga M; Ueda T; Yoshimura A; Takano M; Hontsu S; Uno K; Muro S
Respir Med Case Rep; 2023; 41():101794. PubMed ID: 36583058
[TBL] [Abstract][Full Text] [Related]
5. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis.
Bergqvist V; Hertervig E; Gedeon P; Kopljar M; Griph H; Kinhult S; Carneiro A; Marsal J
Cancer Immunol Immunother; 2017 May; 66(5):581-592. PubMed ID: 28204866
[TBL] [Abstract][Full Text] [Related]
6. Ipilimumab-induced toxicities and the gastroenterologist.
Cheng R; Cooper A; Kench J; Watson G; Bye W; McNeil C; Shackel N
J Gastroenterol Hepatol; 2015 Apr; 30(4):657-66. PubMed ID: 25641691
[TBL] [Abstract][Full Text] [Related]
7. Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis.
Kaneoka A; Okada E; Sugino H; Saito-Sasaki N; Omoto D; Nakamura M
Diagnostics (Basel); 2022 Feb; 12(2):. PubMed ID: 35204571
[TBL] [Abstract][Full Text] [Related]
8. Case Report: Toripalimab: a novel immune checkpoint inhibitor in advanced nasopharyngeal carcinoma and severe immune-related colitis.
Luo C; Chen H; Wu H; Liu Y; Li G; Lun W
Front Immunol; 2023; 14():1298902. PubMed ID: 38077371
[TBL] [Abstract][Full Text] [Related]
9. Ipilimumab-Induced Enteritis without Colitis: A New Challenge.
Messmer M; Upreti S; Tarabishy Y; Mazumder N; Chowdhury R; Yarchoan M; Holdhoff M
Case Rep Oncol; 2016; 9(3):705-713. PubMed ID: 27920706
[TBL] [Abstract][Full Text] [Related]
10. Autoimmune Colitis and Subsequent CMV-induced Hepatitis After Treatment With Ipilimumab.
Uslu U; Agaimy A; Hundorfean G; Harrer T; Schuler G; Heinzerling L
J Immunother; 2015 Jun; 38(5):212-5. PubMed ID: 25962110
[TBL] [Abstract][Full Text] [Related]
11. De novo ulcerative colitis and autoimmune hepatitis after living related liver transplantation from cytomegalovirus-positive donor to cytomegalovirus-negative recipient: a case report.
Sakamoto T; Sato Y; Yamamoto S; Oya H; Hatakeyama K
Transplant Proc; 2012 Mar; 44(2):570-3. PubMed ID: 22410071
[TBL] [Abstract][Full Text] [Related]
12. Ipilimumab and Nivolumab induced steroid-refractory colitis treated with infliximab: A case report.
Nassri AB; Muenyi V; AlKhasawneh A; Ribeiro BS; Scolapio JS; Malespin M; de Melo SW
World J Gastrointest Pharmacol Ther; 2019 Jan; 10(1):29-34. PubMed ID: 30697447
[TBL] [Abstract][Full Text] [Related]
13. Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab.
Zhang HC; Luo W; Wang Y
J Immunother Cancer; 2019 Feb; 7(1):47. PubMed ID: 30777137
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of Infliximab for steroid-resistant immune-related adverse events: A retrospective study.
Kadokawa Y; Takagi M; Yoshida T; Tatsumi A; Fujita K; Inoue T; Ohe S; Nakai Y; Yamamoto S; Otsuka T; Ishihara R; Isei T; Kumagai T; Nishimura K; Imamura F
Mol Clin Oncol; 2021 Apr; 14(4):65. PubMed ID: 33680456
[TBL] [Abstract][Full Text] [Related]
15. Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab.
Tirumani SH; Ramaiya NH; Keraliya A; Bailey ND; Ott PA; Hodi FS; Nishino M
Cancer Immunol Res; 2015 Oct; 3(10):1185-92. PubMed ID: 26100356
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint blockade toxicity among patients with cancer presenting to the emergency department.
Peyrony O; Tieghem Y; Franchitti J; Ellouze S; Morra I; Madelaine-Chambrin I; Flicoteaux R; Baroudjian B; Azoulay E; Chevret S; Fontaine JP
Emerg Med J; 2019 May; 36(5):306-309. PubMed ID: 30910911
[TBL] [Abstract][Full Text] [Related]
17. Extracorporeal Photopheresis as a Treatment Option for Immune-Related Adverse Events: Two Case Reports and a Prospective Study.
Ruf T; Rahimi F; Anz D; Tufman A; Salzer S; Zierold S; Tomsitz D; French LE; Heinzerling L
J Immunother; 2024 Mar; ():. PubMed ID: 38483178
[TBL] [Abstract][Full Text] [Related]
18. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of the Burden of Cytomegalovirus Colonic Reactivation Evaluated by Immunohistochemical Staining in Patients with Active Ulcerative Colitis.
Clos-Parals A; Rodríguez-Martínez P; Cañete F; Mañosa M; Ruiz-Cerulla A; José Paúles M; Llaó J; Gordillo J; Fumagalli C; Garcia-Planella E; Ojanguren I; Cabré E; Guardiola J; Domènech E
J Crohns Colitis; 2019 Mar; 13(3):385-388. PubMed ID: 30346606
[TBL] [Abstract][Full Text] [Related]
20. Effect and safety of granulocyte-monocyte adsorption apheresis for patients with ulcerative colitis positive for cytomegalovirus in comparison with immunosuppressants.
Yoshino T; Nakase H; Matsuura M; Matsumura K; Honzawa Y; Fukuchi T; Watanabe K; Murano M; Tsujikawa T; Fukunaga K; Matsumoto T; Chiba T
Digestion; 2011; 84(1):3-9. PubMed ID: 21311190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
